ARECOR THERAPEUTICS -01

Research ARECOR THERAPEUTICS -01 (6UI) on Bullrun: market cap EUR 23.60M, P/E 31.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker6UI
• ExchangeF
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 23.60M
• P/E31.3
• Financial periodFY2024
• RevenueEUR 5.05M
• Revenue growth10.5%
• Net income-EUR 10.24M
• Free cash flow-EUR 9.18M
• Gross margin30.5%

Valuation Snapshot

latest market cap is EUR 23.60M; P/E is 31.3.

About ARECOR THERAPEUTICS -01

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist.

Frequently asked questions

What is ARECOR THERAPEUTICS -01's market cap?

ARECOR THERAPEUTICS -01's market capitalization is EUR 23.60M.

What is ARECOR THERAPEUTICS -01's P/E ratio?

ARECOR THERAPEUTICS -01's price-to-earnings (P/E) ratio is 31.3.

What does ARECOR THERAPEUTICS -01 do?

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom.